Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 49

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 49
---
 For a further discussion, please see the section titled “Information Regarding the Board of Directors and Corporate Governance— Prohibition on Speculative Trading”.

#### Mirum Pharmaceuticals2025 Proxy Statement39

#### TABLE OF CONTENTS

#### Executive Compensation

#### Stock Ownership Guidelines
Our Compensation Committee established stock ownership guidelines in September 2024. Executive officers’ stock ownership guidelines are based on the value of common stock owned as a multiple of base salary. The guidelines are reviewed annually and revised upward as appropriate to keep pace with competitive and good governance practices. The multiples are set based upon each executive’s position, as set forth below:

| Position                     |     | Stock Ownership Multiple of Base Salary |
| Chief Executive Officer      |     | 3x                                      |
| All other Executive Officers |     | 1x                                      |

Ownership levels are expected to be achieved within five years of the guideline being applicable. As of December 31, 2024, all named executive officers were either in compliance with the guidelines or had additional time to achieve them.

#### Compensation Risk Assessment
Our Compensation Committee reviews the risks arising from our compensation policies and practices applicable to our executive officers and employees and evaluates the policies and practices that could mitigate any such risk. Based on this review, the Compensation Committee does not believe that our compensation policies and practices create risks that are reasonably likely to have a material adverse effect on our company.

#### Compensation Committee Report
Our Compensation Committee has reviewed and discussed with management this Compensation Discussion and Analysis. Based on that review and discussion, we recommended to our Board that the Compensation Discussion and Analysis be included in this Proxy Statement and incorporated into Mirum Pharmaceutical, Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

#### The Compensation Committee

#### Laurent Fischer, M.D., Chair

#### Patrick Heron

#### Saira Ramasastry MS, MPhil

#### William C. Fairey

#### 40Mirum Pharmaceuticals2025 Proxy Statement

#### TABLE OF CONTENTS

#### Executive Compensation

#### Fiscal Year 2024 Summary Compensation Table
The following table presents all of the compensation awarded to or earned by or paid to our named executive officers during the fiscal years indicated below.

| Name and Principal Position(s)           |     |      |     |         | Year | Salary 
 ($)    |           |     | Stock  
 Awards 
 ($)(1) |           |     | Option 
 Awards 
 ($)(2) |           |     | Non-Equity     
 Incentive Plan